Tenofovir/emtricitabine trademark Truvada, is a fixed dose combination of two antiretroviral drugs used for the treatment of HIV. It consists of 300 milligrams of tenofovir and 200 milligrams of emtricitabine. By combining the two agents into one tablet, it reduces the pill burden and increases compliance with antiretroviral therapy. The drug has also found some potential as a preventative measure if taken daily or weekly leading up to exposure, though human clinical trials are ongoing .
Truvada was developed by Gilead Sciences and approved by the Untited States' Food and Drug Administration in 2004.
A combination pill containing Truvada and efavirenz (Sustiva) is also available and is marketed as Atripla.